Literature DB >> 27234923

Intravitreal Bevacizumab as an adjunct to laser in the management of adult onset Coats' disease.

Neha Goel1, Vinod Kumar2.   

Abstract

Entities:  

Keywords:  Adult onset Coats’ disease; Intravitreal bevacizumab; Laser photocoagulation; Macular edema; Macular exudation; Vascular endothelial growth factor

Mesh：

Substances：

Year:  2016        PMID： 27234923     DOI： 10.1007/s00417-016-3390-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  4 in total

1.  Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease.

Authors:  Saemi Park; Han Joo Cho; Dong Won Lee; Chul Gu Kim; Jong Woo Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-03       Impact factor: 3.117

2.  Role of intravitreal bevacizumab in adult onset Coats' disease.

Authors:  Neha Goel; Vinod Kumar; Anisha Seth; Usha Kaul Raina; Basudeb Ghosh
Journal:  Int Ophthalmol       Date:  2011-03-25       Impact factor: 2.031

3.  Classification and management of Coats disease: the 2000 Proctor Lecture.

Authors:  J A Shields; C L Shields; S G Honavar; H Demirci; J Cater
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

4.  Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection.

Authors:  Jong Hwa Jun; Yu Cheol Kim; Kwang Soo Kim
Journal:  Korean J Ophthalmol       Date:  2008-09
  4 in total
  2 in total

1.  Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease.

Authors:  Gilda Cennamo; Daniela Montorio; Chiara Comune; Maria Paola Laezza; Matteo Fallico; Maria Elena Lionetti; Michele Reibaldi
Journal:  Front Med (Lausanne)       Date:  2021-01-21

2.  The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.

Authors:  Longli Zhang; Yifeng Ke; Wei Wang; Xueying Shi; Kaiwen Hei; Xiaorong Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-16       Impact factor: 3.117
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.